A Phase II Study of Cisplatin Plus Etoposide (PE) Plus Bevacizumab (NSC 704865) for Previously Untreated Extensive Stage Small Cell Lung Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 14 May 2014 Biomarkers information updated
- 09 Feb 2010 Actual patient number (65) added as reported by ClinicalTrials.gov.
- 02 Jun 2009 Actual initiation date (Mar 2009) added as reported by ClinicalTrials.gov.